
CLAIMS

1. A tetrahydropyridine compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[Formula I]



wherein,

n is 1, 2 or 3;

R_1 is C1-C6 alkyl or C1-C6 haloalkyl;

R_2 is hydrogen or C1-C6 alkyl;

R_3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, -OH or halogen;

L is C3-C7 cycloalkyl, aryl, heteroaryl or null, wherein at least one H of C3-C7 cycloalkyl, aryl or heteroaryl may be substituted with halogen, C1-C6 alkyl, C1-C6 haloalkyl, $-NR_AR_B$ or -OH;

D is C≡C, C3-C7 cycloalkyl, aryl, heteroaryl or null, wherein at least one H of C3-C7 cycloalkyl, aryl or heteroaryl may be substituted with halogen, C1-C6 alkyl, C1-C6 haloalkyl, $-NR_AR_B$ or -OH;

E is C≡C, C3-C7 cycloalkyl, aryl, heteroaryl or null, wherein at least one H of C3-C7 cycloalkyl, aryl or heteroaryl may be substituted with halogen, C1-C6 alkyl, C1-C6 haloalkyl, $-NR_AR_B$ or -OH;

G is C1-C6 alkyl, C3-C7 cycloalkyl, 4-6 membered heterocycloalkyl, aryl or heteroaryl,

wherein at least one H of C1-C6 alkyl may be substituted with halogen, $-NR_AR_B$, -OH or $-OR_C$,

at least one H of C3-C7 cycloalkyl or 4-6 membered heterocycloalkyl may be substituted with C1-C6 alkyl, C1-C6 alkyl-NR_AR_B, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkyl-OR_C, $-NR_AR_B$, -OH, -(C=O)-C1-C6 alkyl or $-S(=O)_2$-C1-C6 alkyl,

at least one H of aryl or heteroaryl may be substituted with C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkyl-NR_AR_B, halogen, nitro, cyano, $-NR_AR_B$, -OH, $-OR_C$, $-S(=O)_2$-C1-C6 alkyl, $-S(=O)_2-NR_AR_B$ or $-N-S(=O)_2$-C1-C6 alkyl;

R_A and R_B are each independently hydrogen or C1-C6 alkyl, or R_A and R_B may be linked

together to form 4-6 membered ring, wherein the 4-6 membered ring may have O or S atom and at least one H of the 4-6 membered ring may be substituted with halogen, -OH or C1-C6 hydroxyalkyl;

R_C is C1-C6 alkyl, C1-C6 hydroxyalkyl, -(C=O)-NR_DR_E or -$S(=O)_2$-C1-C6 alkyl; and

R_D and R_E are each independently hydrogen or C1-C6 alkyl.

2. The tetrahydropyridine compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1:

wherein,

n is 1 or 2;

R_1 is C1-C6 alkyl;

R_2 is C1-C6 alkyl;

R_3 is hydrogen;

L is aryl, heteroaryl or null, wherein at least one H of aryl or heteroaryl may be substituted with halogen, C1-C6 alkyl or C1-C6 haloalkyl;

D is C≡C or null;

E is C≡C or null;

G is C1-C6 alkyl, C3-C7 cycloalkyl, 4-6 membered heterocycloalkyl, aryl or heteroaryl,

wherein at least one H of C1-C6 alkyl may be substituted with halogen, -NR_AR_B, -OH or -OR_C,

at least one H of 4-6 membered heterocycloalkyl may be substituted with C1-C6 alkyl, -(C=O)-C1-C6 alkyl or -$S(=O)_2$-C1-C6 alkyl,

at least one H of aryl or heteroaryl may be substituted with C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkyl-NR_AR_B, halogen, nitro, cyano, -NR_AR_B, -OH, -OR_C, -$S(=O)_2$-C1-C6 alkyl or -$S(=O)_2$-NR_AR_B;

R_A and R_B are each independently hydrogen or C1-C6 alkyl, or R_A and R_B may be linked together to form 4-6 membered ring, wherein the 4-6 membered ring may have O atom and at least one H of the 4-6 membered ring may be substituted with C1-C6 hydroxyalkyl;

R_C is C1-C6 alkyl, C1-C6 hydroxyalkyl, -(C=O)-NR_DR_E or -$S(=O)_2$-C1-C6 alkyl; and

R_D and R_E are each independently hydrogen.

3. The tetrahydropyridine compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 2:

wherein,

n is 1 or 2;

R_1 is C1-C6 alkyl;

R_2 is C1-C6 alkyl;

R_3 is hydrogen;

L is phenyl, pyridinyl or null, wherein at least one H of phenyl or pyridinyl may be substituted with halogen, C1-C6 alkyl or C1-C6 haloalkyl;

D is C≡C or null;

E is C≡C or null;

G is C1-C6 alkyl, C3-C6 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, pyridinyl, furanyl, thiophenyl or imidazolyl,

wherein at least one H of C1-C6 alkyl may be substituted with halogen, $-NR_AR_B$, -OH or $-OR_C$,

at least one H of 4-6 membered heterocycloalkyl may be substituted with C1-C6 alkyl, -(C=O)-C1-C6 alkyl or $-S(=O)_2$-C1-C6 alkyl,

at least one H of phenyl, pyridinyl, furanyl, thiophenyl or imidazolyl may be substituted with C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkyl-NR_AR_B, halogen, nitro, cyano, $-NR_AR_B$, -OH, $-OR_C$, $-S(=O)_2$-C1-C6 alkyl or $-S(=O)_2-NR_AR_B$;

R_A and R_B are each independently hydrogen or C1-C6 alkyl, or R_A and R_B may be linked together to form 4-6 membered ring, wherein the 4-6 membered ring may have O atom and at least one H of the 4-6 membered ring may be substituted with C1-C6 hydroxyalkyl;

R_C is C1-C6 alkyl, C1-C6 hydroxyalkyl, $-(C=O)-NR_DR_E$ or $-S(=O)_2$-C1-C6 alkyl; and

R_D and R_E are each independently hydrogen.

4. The tetrahydropyridine compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 3, wherein the compound is selected from the group consisting of compounds described in the following table:

1) 4-(4-(4-((4-(dimethylamino)phenyl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

2) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(phenylethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

3) N-hydroxy-4-(4-(4-((4-methoxyphenyl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

4) 4-(4-(4-(cyclopropylethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

5) N-hydroxy-4-(4-(4-(4-hydroxybut-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

6) 4-(4-(4-(hex-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

7) 4-(4-(4-(3-(dimethylamino)prop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

8) N-hydroxy-4-(4-(4-(3-hydroxybut-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

9) 4-(4-(4-(cyclopentylethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

10) 4-(4-(4-(cyclohexylethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

11) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(pent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

13) N-hydroxy-2-methyl-4-(4-(4-(4-methylpent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-(methylsulfonyl)butanamide;

14) 4-(4-(4-(5-chloropent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

15) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(3-(pyrrolidin-1-yl)prop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

16) 4-(4-(4-(3-(diethylamino)prop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

17) N-hydroxy-4-(4-(4-(3-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)prop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

18) N-hydroxy-4-(4-(4-(5-hydroxypent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

19) 5-(4-(1-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pent-4-yn-1-yl methanesulfonate;

20) 4-(4-(4-(5-(dimethylamino)pent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

21) 4-(4-(4-(5-aminopent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-

hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

22) N-hydroxy-4-(4-(4-(3-hydroxyprop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

23) N-hydroxy-4-(4-(4-(3-methoxyprop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

24) N-hydroxy-4-(4-(4-(3-(3-hydroxypropoxy)prop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

25) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

26) 3-(4-(1-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)prop-2-yn-1-yl carbamate;

27) 5-(4-(1-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pent-4-yn-1-yl carbamate;

28) N-hydroxy-4-(4-(4-(5-methoxypent-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

29) N-hydroxy-4-(4-(4-(6-hydroxyhex-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

30) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(6-morpholinohex-1-yn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

31) 4-(4-(4-(3-(dimethylamino)prop-1-yn-1-yl)-3-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

32) 4-(4-(4-(3-(dimethylamino)prop-1-yn-1-yl)-3,5-difluorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

33) 4-(4-(4-(3-(dimethylamino)prop-1-yn-1-yl)-2-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

34) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(thiophen-2-ylethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

35) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-((4-nitrophenyl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

36) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(pyridin-3-ylethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

37) N-hydroxy-4-(4-(4-((4-hydroxyphenyl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

38) N-hydroxy-2-methyl-4-(4-(4-((1-methyl-1H-imidazol-4-yl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-(methylsulfonyl)butanamide;

39) N-hydroxy-2-methyl-4-(4-(4-((1-methylazetidin-3-yl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-(methylsulfonyl)butanamide;

40) 4-(4-(4-((1-acetylazetidin-3-yl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

41) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-((1-(methylsulfonyl)azetidin-3-yl)ethynyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

42) 4-(4-(3-fluoro-4-(7-hydroxyhepta-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

43) 4-(4-(3-fluoro-4-(6-hydroxyhexa-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

44) 4-(4-(4-(cyclopropylbuta-1,3-diyn-1-yl)-3-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

45) 4-(4-(4-(5-(dimethylamino)penta-1,3-diyn-1-yl)-3-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

46) N-hydroxy-4-(4-(4-(7-hydroxyhepta-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

47) N-hydroxy-4-(4-(4-(6-hydroxyhexa-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

48) N-hydroxy-4-(4-(4-(5-hydroxypenta-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

49) 4-(4-(4-(5-(dimethylamino)penta-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

50) N-hydroxy-4-(4-(4-(5-methoxypenta-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

51) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(phenylbuta-1,3-diyn-1-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

52) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(pyridin-4-ylethynyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

53) 4-(4-((4-bromophenyl)ethynyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

54) N-hydroxy-4-(4-(7-hydroxyhepta-1,3-diyn-1-yl)-3,6-dihydropyridin-1(2H)-yl)-2-

methyl-2-(methylsulfonyl)butanamide;

55) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(pyridin-4-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

56) 4-(4-([1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

57) 4-(4-(4'-chloro-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

58) 4-(4-(4'-fluoro-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

59) N-hydroxy-4-(4-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

60) 4-(4-(3'-fluoro-4'-methoxy-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

61) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(pyridin-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

62) 4-(4-(4-(6-fluoropyridin-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

63) 4-(4-(4-(furan-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

64) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

65) N-hydroxy-4-(4-(4'-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

66) 4-(4-(4'-cyano-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

67) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4'-pentyl-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

68) 4-(4-(4'-(azetidin-1-ylsulfonyl)-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

69) 4'-(1-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-4-yl)-[1,1'-biphenyl]-4-yl methanesulfonate;

70) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(thiophen-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

71) N-hydroxy-4-(4-(4-(3-methoxythiophen-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

72) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4-(4-methylthiophen-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

73) 4-(4-(4'-(ethylsulfonyl)-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

74) N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-(4'-(morpholinomethyl)-[1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)butanamide;

75) N-hydroxy-4-(6-(3-methoxyprop-1-yn-1-yl)-3',6'-dihydro-[3,4'-bipyridin]-1'(2'H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

76) 3-(4-([1,1'-biphenyl]-4-yl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)propanamide;

77) 4-(4-(4-(3-(dimethylamino)prop-1-yn-1-yl)-3-methylphenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; and

78) 4-(4-(4-(3-(dimethylamino)prop-1-yn-1-yl)-3-(trifluoromethyl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide.

5. Use of the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in preparation of a medicament for treating bacterial infection.

6. The use of claim 5, wherein the bacterial infection is caused by Gram-negative bacteria.

7. The use of claim 6, wherein the bacterial infection is selected from the group consisting of nosocomial pneumonia, urinary tract infections, systemic infection, skin and soft tissue infection, surgical infections, intraabdominal infection, lung infection, endocarditis, diabetic foot infection, osteomyelitis, and central nervous system infection.

8. A pharmaceutical composition comprising, as an active ingredient, the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

9. The pharmaceutical composition according to claim 8 for preventing or treating a bacterial infection.

10. Use of the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in preparation of a medicament for inhibiting UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).